INTRODUCTION
Saposins (sphingolipid activator proteins) A, B, C and D are ~80 amino acid, lysosomal glycoproteins that are encoded by a single gene termed prosaposin (1) (2) (3) (4) . The proteolytic processing of prosaposin to the individual saposins occurs predominantly in acidified compartments including the lysosome (5, 6) . The physiological importance of this locus has been demonstrated by the genetic deficiencies of individual saposins or prosaposin that lead to various glycosphingolipid storage diseases (7) (8) (9) (10) . For example, saposin B deficiency leads to sulfatide accumulation and a metachromatic leukodystrophy-like disease (11) that is similar to the deficiency of arylsulfatase A, the cognate enzyme. Saposin C enhances acid β-glucosidase (GCase) activity and its deficiency leads to a Gaucher-like disease with glucosylceramide accumulation in cells (9, 12) . Deficiencies of saposin A and D have not been described in humans.
Deficiency of saposin A in mice leads to a late onset, chronic form of globoid cell leukodystrophy (13) . Total deficiency of human or mouse prosaposin results in the storage of multiple glycosphingolipids (GSLs) in a variety of organs (7, 8, 14) Saposins enhance the activity of their respective cognate lysosomal enzymes by different mechanisms to achieve optimal in vitro and in vivo degradation of GSLs (15) (16) (17) . Saposin B in a dimeric shell structure facilitates the partial extraction of GSLs from membranes and presentation of sulfatides or globotriaosylceramide to arylsulfatase A or α-galactosidase A, respectively (18, 19) . Saposin C promotes GCase activity by inducing a conformation change in the enzyme at acidic pH (20, 21) . In vitro, both saposin A and C enhance GCase activity and negatively charged phospholipids are required for their actions (20, 22) , but they have a different membrane interaction modes (20) . In vivo, saposin A and C enhance galactosylcerebrosidase and GCase activities, respectively (23) . Saposin D stimulated partially purified acid ceramidase for the degradation of ceramide (24) . Importantly, selected non-physiologic detergents can obviate the need for negatively charged phospholipids and/or saposins in these GCase assays and provide estimates of its total catalytic power within cells (25) .
Although the involvement of saposins in the degradation of glycosphingolipids is well established, their in vivo mechanisms of action are not fully understood. Reductions of GCase, acid ceramidase and galactosylcerebrosidase activities are present in extracts of tissues/cells from prosaposin knockout (PS-/-) mice and prosaposin deficient humans (8, 14, 26) . These data suggested that saposins might have roles, in addition to being activators, as protective or chaperone proteins for their cognate enzyme. Data presented here support such a role for the saposin C in protecting GCase from proteolysis in lysosomes.
EXPERMENTAL PROCEDURES

Materials:
The following were from commercial sources; Leupeptin (Calbiochem, San Diego, CA Cell culture: Hepatocyte cultures were established from the wild type (WT);TAg+ and PS-/-;T Ag+ mice. These mice were generated by breeding WT or PS-/-mice with the immortomouse (T Ag+) that contains the temperature sensitive SV40 T antigen mutant driven by the mouse major histocompatibility complex H-2Kb promoter. The PS-/-;TG mice were obtained by breeding of PS+/-mice with the mice containing the mouse prosaposin transgene (TG), then back-crossing to obtain PS-/-;TG mice (27) . TG expression was driven by the 3-phosphoglycerate kinase promoter. The fibroblast cultures were established as described (27) . Mouse hepatocytes (32 o C) and fibroblasts (37 o C) and human fibroblasts were maintained in DMEM+10% FBS+100 units/ml penicillin and 100 mg/ml streptomycin. For leupeptin treatment, the cells were incubated with media containing leupeptin (50 or 100 µM) for 48 hours with one replacement of fresh medium and leupeptin at 24 hours. For the saposin loading experiments, human prosaposin deficient fibroblasts were incubated with medium containing human saposin C or D (75 µg/ml) for 4 days. The pure human saposins were produced in E. coli using the pET 21a system (22) .
Enzyme assays: The cells or tissues were lysed in 1% sodium taurocholate/1% Triton X-100.
GCase activities were determined fluorometrically with 4MU-Glc (28 Immunoblots: The cell lysates were subjected to 12.5 % SDS gel and electroblotted onto PVDF membranes. After blocking in 1% milk, GCase and β-actin were detected by incubation with rabbit anti-mouse GCase antiserum (1/1000) or goat anti-actin antibody (1/300) diluted in 0.5%
BSA, followed by treatment with alkaline phosphatase conjugated to goat anti-rabbit (1/3000) or donkey anti-goat IgG (1/500) diluted in TTBS. GCase in human fibroblast cells were detected by rabbit anti-human GCase antiserum (1/1500) in 1% milk/1% BSA. The blots were quantified by Molecular Dynamics ImageQuant Software. The values obtained for GCase bands (Mr=65,000)
were normalized to the actin bands. Rabbit anti-mouse GCase was raised against recombinant mouse GCase produced in E. coli using the pET 21a system (22) .
Pulse-chase studies: Proteins in mouse and human fibroblasts were radiolabeled for 1 hour with 150 µCi [ 35 S]cysteine/methionine and chased with non-radioactive media for the indicated time.
The radioactively labeled GCase protein in cell lysates were immunoprecipitated using anti-mouse or human GCase antiserum (27) . The fibroblasts were matched for passage number and strain. The radioactive GCase bands were quantified by Molecular Dynamics ImageQuant Software.
RNA analyses: Total RNA was extracted using Trizol reagent. Northern blots were performed as described (27) 
RESULTS and DISCUSSION
Reduction of GCase in prosaposin knockout (PS-/-) mice and recovery of GCase activity in PS-
/-;TG mice: Compared to those from strain matched PS+/+ (WT) tissues, the in vitro GCase activities from tissue extracts of PS-/-mice were significantly reduced (65-80 %) in liver and kidney. The slight decrease of GCase activity in cerebrum was not significant (Fig. 1A) . In comparison, in vitro GCase activities were increased in extracts of liver and cultured fibroblasts from PS-/-;TG mice. By real-time RT-PCR analysis, the TG mRNA from liver and cultured fibroblasts of PS-/-;TG mice was at ~5-7% relative to the endogenous prosaposin in the corresponding WT samples. This low level of prosaposin TG expression was sufficient to increase the GCase activity by over 2-fold relative to PS-/-mice (Fig. 1B) . These results established a relationship between PS expression, the presence of saposin/prosaposin protein, and the in vitro level of GCase activity. Clearly, small amounts of PS expression were required to reestablish GCase activity. Importantly for these studies, the detergent assays used for estimating GCase in vitro activity do not require negatively charged phospholipids or saposin C.
Indeed, the detergents (taurocholate and triton X-100) replace the function of these two more natural activators and provide an assessment of the maximal catalytic power of GCase in cells (25) . Thus, the activities do not related to the in vivo levels, but rather reflect the level of catalytically active GCase within cells. Such reductions could be due to decreased synthesis of GCase, its folding or its stability within the cells.
Reduction of GCase protein in PS-/-cells:
To address the mechanism for the GCase activity reductions, fibroblast and hepatocyte cultures were established from the wild type and PS-/-mice and used for immunoblot analysis. To eliminate the potential for diminished GCase gene expression, GCase RNA levels were determined by Northern analyses and were found to be the same as in WT and PS-/-samples ( Fig. 2A) . Importantly, the GCase activities in the PS-/-cell extracts were reduced by ≥50% relative to WT (Fig. 2B) . Immunoblots using anti-mouse GCase antiserum showed a concordant decrease in GCase protein (Fig. 2C) . Essentially identical results
were obtained with prosaposin deficient cultured human fibroblasts using rabbit anti-human
GCase antibodies (Fig. 5) . These results show that the reduction of GCase activity in PS-/-cells is due to a decrease of GCase protein and not because of misfolding of GCase into an inactive conformer. However, this does not exclude the potential for diminished translation of the normal amounts of GCase mRNA.
Turnover of GCase protein in PS-/-and WT cells:
Pulse-chase studies were conducted to evaluate the synthetic levels of GCase protein and its stability in both mouse and human fibroblasts. Following metabolic labeling and chase, GCase in the cell lysates were immunoprecipitated using anti-mouse or anti-human GCase antibodies. Quantitative immunoprecipitation of the GCase in cultured fibroblasts showed essentially the same levels of GCase signal from WT and PS-/-cells at 0 hr of chase (Fig. 3) . This excludes the possibility of a grossly abnormal translation of the normal amounts of GCase mRNA in PS-/-cells. However, in WT cultured fibroblasts GCase protein was detectible for up to 72 hrs of chase. In contrast,
GCase in PS-/-cells was at very low levels after 24 hours of chase (Fig. 3) . The GCases in WT cells have t 1/2 > 24 hr and in PS-/-cells have t 1/2 ~1 hr in mouse or ~ 8 hr in human. These results
show that essentially normal amounts of GCase are synthesized in PS-/-cells and that it was degraded at a much greater rate than in WT cells. Such enhanced degradation could occur by proteolysis in different compartments including the ER, Golgi or endosome/lysosomes. To establish the mechanism of saposin/prosaposin effect on GCase degradation, studies were conducted with protease inhibitors that exert their major effects in the lysosome.
GCase activity and protein in PS-/-cells treated with protease inhibitors:
PS-/-cultured mouse fibroblasts and hepatocytes were incubated with leupeptin, a cysteine protease inhibitor.
Leupeptin inhibits protein degradation in the lysosome by 85% and non-lysosome compartments by 15% (30) . After 48 hours of leupeptin exposure, both GCase activity and protein levels increased by ~1.7-to 2-fold ( Fig. 4A and B) . The final GCase activity and protein levels were comparable to those in WT fibroblasts (Fig. 4) . Leupeptin treatment had little or no effect on WT In prosaposin deficient human fibroblast cells, GCase RNA is at same level as WT control (Fig.   5A ). Consistent with mouse samples, GCase activity and protein levels showed increases of 2-and 1.7-fold respectively after incubation with leupeptin containing medium for 48 hours ( Fig.   5A and B). Cathepsin inhibitor II, a selective lysosomal cysteine protease inhibitor, increased GCase activity and protein by ~1.3 fold in human PS-/-fibroblasts (data not shown). Leupeptin ( Fig. 5 ) and cathepsin inhibitor II treatment had no significant effect on GCase activity and protein in WT controls. The same results were obtained from primary human fibroblast cells.
These results implicate the cysteine/aspartic protease participation in the degradation of GCase in the lysosome. In these cells leupeptin, cathepsin inhibitor II or pepstatin had no effect on β-glucuronidase activity, a soluble lysosomal enzyme that not involved in GSL metabolism.
Saposin C led to recovery GCase activity and protein in PS-/-cells: PS-/-cultured human fibroblasts were incubated with human saposin C or saposin D in the medium. The cells loaded with saposin C showed significant increase of GCase activity and protein ( Fig. 6A and B) .
Saposin D had no effect on GCase in PS-/-cells (Fig. 6 ). The effects of saposin A and B on GCase activity were studied using the fibroblast from saposin A deficient mice and a human saposin B deficient patient. No alteration of GCase activity was observed in those cells.
The results from present study support saposin C as the protector for GCase. Saposins A and C enhance in vitro GCase activity (22, 23) , but only isolated saposin C deficiency leads to glucosylceramide storage and "Gaucher disease-like" phenotype (9, 12) . In saposin A mutant mice, no accumulation of glucosylcerebroside was found (13) and GCase activity was not altered in fibroblasts from such mutant mice. Thus, saposin A is not a physiologically important activator or protector for GCase. Furthermore, saposin B and D do not have any effect on GCase activity (31). GCase activity was not reduced in human saposin B deficient fibroblast. Loading saposin D to PS-/-cells had no effect on GCase. These results show that saposin C has a novel role as the anti-proteolytic protector for GCase in addition to being enzymatic activator.
These studies indicate that the enhanced degradation of GCase in prosaposin deficient mice and humans occurs largely in the lysosome. This has two implications: 1) that GCase is normally It is unlikely that all the glycosphingolipid activators would have protective functions for their cognate enzyme. β-Hexosaminidase A, the cognate enzyme for GM 2 activator, maintained nearly normal activity in GM 2 activator deficient mice (36) and humans (37) . Arylsulfatase A that requires saposin B for optimal activation showed normal levels in both human and mice with either saposin B or prosaposin deficiency (14, 38, 39) . The level of arylsulfatase A protein was normal in PS-/-fibroblasts (Sun, et al., unpublished observation). In comparison, saposin A is essential for galactosylcerebrosidase to achieve maximal activity (40) . The mouse models with deficient saposin A or prosaposin have decreased in vitro galactosylcerebrosidase activity (13, 14) . Decreased acid ceramidase activity also was observed in prosaposin deficient patient cells (26, 41) and prosaposin deficient mouse tissues. However, the acid ceramidase protein level was not altered in PS-/-samples (Sun, et al., unpublished observation). Whether galactosylcerebrosidase was protected by saposin A and the possibility of saposin D being the chaperone for acid ceramidase is under investigation.
In vitro and ex vivo turnover studies shows that the GCase interacts with the inner lysosomal membrane (21, 42, 43) . Using artificial membrane systems of negatively charged phospholipids, saposin C facilitates the association of GCase with the membranes to favor the degradation of glucosylcerebroside (44) . The membrane attachment is essential for GCase stability and catalytic function. In addition to its activator functions, saposin C, as a protector, might play the role in enhancing the stability and efficiency of GCase in vivo by facilitating the association of enzyme to membrane. These functions of saposin C have implications for understanding the molecular pathogenesis of Gaucher disease and development of more efficient therapies. The majority of GCase mutations that cause Gaucher disease disrupt inherent catalytic function and/or the proteolytic stability of the mutant enzyme (45, 46) . The latter results primarily from misfolding of GCase, but one could envision specific mutations that preclude or diminish interaction of GCase and saposin C. This could lead to an unstable enzyme with that could have nearly normal in vitro intrinsic residual activity as assessed with detergents. Certainly, mutations that affect the saposin C/GCase interaction site would lead to greater decreases of in vivo activity than expected from the GCase mutation alone. Similarly, disruption of the normal stoichiometry between GCase and saposin C would lead to proteolytic susceptibility of GCase. For example, GCase can be supplied by delivery to macrophages as purified enzyme or by over expression in selected cells, e.g., a gene therapy approach. The delivery of large excesses of GCase to these cells could overwhelm the saposin C available for interaction. This excess enzyme would be very susceptible to proteolytic degradation and diminish the expected therapeutic benefit. Thus, preservation of the appropriate stoichiometry of saposin C and GCase could significantly enhance the efficacy/costbenefit of such therapeutic approaches. 
